iqvia weight loss prescriptions semaglutide tirzepatide q3 2024 us iqvia glp-1 prescriptions q3 2024 semaglutide tirzepatide Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA's 2024 Update-bsmoothhr Obesity Interest Sparks Dealmaking Activity

Improvement of metabolic status: Animal experiments show that MSTN-IP7 can reduce inflammation in adipose tissue, enhance liver lipid metabolism, and have potential regulatory effects on metabolic disorders related to obesity and diabetes

Soriano, S., et al

At 72 weeks, tirzepatide patients lost an average of 20.2% of their body weight compared to 13.7% with semaglutide a difference of 6.5 percentage points

Our team can provide an invoice of the services you received, and you can submit that to your insurance company for a possible reimbursement

More serious but less common side effects include: Pancreatitis: This is inflammation of the pancreas, which can cause severe stomach pain, nausea, and vomiting